Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database

被引：0
|
作者：
Sangjin Shin
Chan Mi Park
Hanbyeol Kwon
Kyung-Hun Lee
机构：
[1] National Evidence-based healthcare Collaborating Agency,Department of Internal Medicine
[2] Seoul National University Hospital,Cancer Research Institute
[3] Seoul National University College of Medicine,undefined
来源：
BMC Cancer | / 16卷
关键词：
Pancreatic cancer; Gemcitabine; Erlotinib; Comparative effectiveness research; National database;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
    Shin, Sangjin
    Park, Chan Mi
    Kwon, Hanbyeol
    Lee, Kyung-Hun
    BMC CANCER, 2016, 16
  • [2] Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
    Kang, Sora
    Yoo, Changhoon
    Lee, So Heun
    Oh, Dongwook
    Song, Tae Jun
    Lee, Sang Soo
    Jeong, Jae Ho
    Park, Do Hyun
    Seo, Dong Wan
    Park, Jin-hong
    Hwang, Dae Wook
    Song, Ki Byung
    Lee, Jae Hoon
    Lee, Woohyung
    Kwak, Bong Jun
    Hong, Sarang
    Chang, Heung-Moon
    Ryoo, Baek-Yeol
    Kim, Kyu-pyo
    Kim, Song Cheol
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [3] A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers
    Wang, Ying
    Camateros, Pierre
    Cheung, Winson Y.
    JOURNAL OF GASTROINTESTINAL CANCER, 2019, 50 (01) : 62 - 68
  • [4] A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers
    Ying Wang
    Pierre Camateros
    Winson Y. Cheung
    Journal of Gastrointestinal Cancer, 2019, 50 : 62 - 68
  • [5] Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis
    Furuse, Junji
    Gemma, Akihiko
    Ichikawa, Wataru
    Okusaka, Takuji
    Seki, Akihiro
    Ishii, Tadashi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (09) : 832 - 839
  • [6] Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
    Guoqing Ouyang
    Zhipeng Liu
    Shengfu Huang
    Qianglong Li
    Li Xiong
    Xiongying Miao
    Yu Wen
    World Journal of Surgical Oncology, 14
  • [7] Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
    Ouyang, Guoqing
    Liu, Zhipeng
    Huang, Shengfu
    Li, Qianglong
    Xiong, Li
    Miao, Xiongying
    Wen, Yu
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2016, 14
  • [8] Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer
    Maraveyas, A.
    Waters, J.
    Roy, R.
    Fyfe, D.
    Propper, D.
    Lofts, F.
    Sgouros, J.
    Gardiner, E.
    Wedgwood, K.
    Ettelaie, C.
    Bozas, G.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (09) : 1283 - 1292
  • [9] Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
    de Jong, Evelien J. M.
    Janssen, Quisette P.
    Simons, Tessa F. A.
    Besselink, Marc G.
    Bonsing, Bert A.
    Bouwense, Stefan A. W.
    Geurts, Sandra M. E.
    Homs, Marjolein Y., V
    de Meijer, Vincent E.
    Tjan-Heijnen, Vivianne C. G.
    van Laarhoven, Hanneke W. M.
    Valkenburg-van Iersel, Liselot B. J.
    Wilmink, Johanna W.
    van der Geest, Lydia G.
    Koerkamp, Bas Groot
    de Vos-Geelen, Judith
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (10) : 1654 - 1663
  • [10] The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence
    Prejac, Juraj
    Hamzic, Dora Tomek
    Librenjak, Niksa
    Gorsic, Irma
    Kekez, Domina
    Plestina, Stjepko
    MEDICINE, 2022, 101 (39) : E30566
12345